Most popular now
Advertisement

Australian Researchers Develop mRNA Nasal Drops to Boost Memory and Combat Alzheimer’s in Mice

Australian Researchers Develop mRNA Nasal Drops to Boost Memory and Combat Alzheimer’s in Mice
Australian Researchers Develop mRNA Nasal Drops to Boost Memory and Combat Alzheimer’s in Mice Photo: НВ — Техно

Inspired by 'Flowers for Algernon'

According to НВ — Техно: Scientists in Australia have created nasal drops aimed at enhancing memory, drawing inspiration from Daniel Keyes’ novel. At the University of Sydney, researchers have formulated experimental mRNA-based nasal drops that improve learning and memory in aged mice, while also preventing cognitive decline in mice engineered with the 5XFAD Alzheimer’s disease model. Delivering brain-derived neurotrophic factor (BDNF) directly through the nasal passage allows the treatment to bypass the blood-brain barrier effectively.

Development and Experimental Findings

Led by Professor Greg Neely and Dr. Maria Bergamasco at the Dr. John and Anna Chong Functional Genomics Laboratory at the University of Sydney, the team encapsulated instructions for producing BDNF within lipid nanoparticles for the nasal spray. BDNF plays a critical role in supporting neuron survival, plasticity, and memory formation. Declining levels of BDNF are closely linked to aging and the progression of Alzheimer's disease.

The therapy was tested on older mice and those genetically modified to model Alzheimer’s (5XFAD). Administered intranasally twice weekly from two to four months of age, the treatment prevented cognitive decline in mice up to four months old and enhanced hippocampal neurogenesis. However, the amount of amyloid plaques in the brain remained unchanged after treatment, indicating the therapy’s benefits stem from maintaining neuron health and connectivity rather than plaque reduction.

This mRNA-lipid nanoparticle technology is similar to the platform used in COVID-19 vaccines. The study detailing these promising results was published in the journal Advanced Science. Researchers aim to evaluate the therapy’s safety and move towards human clinical trials within the next two years.

Given the growing global impact of Alzheimer’s and other cognitive disorders, this breakthrough could mark a significant advancement in treatment options. The success of these mRNA nasal drops in animal models highlights the potential for mRNA-based therapies to address neurodegenerative diseases. Should human trials confirm these findings, it could open new pathways for improving memory and slowing cognitive decline in aging populations.

While advancements in mRNA therapies show promise for cognitive enhancement, recent findings from Dutch researchers reveal crucial insights into how immature neurons may protect the brain from Alzheimer's symptoms. Understanding these mechanisms could further inform the development of effective treatments for neurodegenerative diseases.

Advertisement

Read also

Advertisement

Advertisement

Advertisement